Grimer Robert J, Sommerville Scott, Warnock David, Carter Simon, Tillman Roger, Abudu Adesegun, Spooner David
The Royal Orthopaedic Hospital Oncology Service, Royal Orthopaedioc Hospital, Bristol Road South Northfield, Birmingham B31 2AP, UK.
Eur J Cancer. 2005 Mar;41(4):578-83. doi: 10.1016/j.ejca.2004.11.012. Epub 2005 Jan 5.
We report on the management and outcome of 96 patients who developed local recurrence (LR) after having definitive primary treatment with chemotherapy and surgery for non-metastatic osteosarcoma. LR developed at a median of 11 months from initial surgical treatment. 18% of patients had metastases prior to the diagnosis of LR and 23% were found to have metastases synchronously. The prognosis for this group with metastases was 14% survival at 2 years. In the 57 patients without metastases at the time of development of LR, survival was 51% at 2 years and 41% at 5 years. Treatment was by excision of the LR and radiotherapy or by amputation. The only significant prognostic factors identified were the presence of metastases at the time of development of LR (P < 0.0001) and small size of the LR. The role of adjuvant chemotherapy was unclear. Whilst every attempt should be made to avoid LR, patients who develop LR are curable, particularly if they do not have metastases at the time of diagnosis of the LR.
我们报告了96例非转移性骨肉瘤患者在接受化疗和手术的确定性初始治疗后出现局部复发(LR)的治疗情况及结果。LR发生于初次手术治疗后的中位时间为11个月。18%的患者在LR诊断前已有转移,23%的患者被发现同时发生转移。该伴有转移的患者组2年生存率为14%。在LR发生时无转移的57例患者中,2年生存率为51%,5年生存率为41%。治疗方法为切除LR并进行放疗或截肢。唯一确定的显著预后因素是LR发生时是否存在转移(P<0.0001)以及LR体积较小。辅助化疗的作用尚不清楚。虽然应尽一切努力避免LR,但发生LR的患者是可治愈的,特别是如果他们在LR诊断时没有转移。